Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$20.94 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.21M

Average 2.11M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$345.10M

FY 2025 · Annual

Investing Cash Flow

-$121.44M

FY 2025 · Annual

Financing Cash Flow

$478.05M

FY 2025 · Annual

+6079.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
Deferred Income Tax00000
Stock-Based Compensation43.57M84.32M98.65M120.66M94.24M
Change in Working Capital111.25M251.63M(116.46M)(110.22M)(131.02M)
Accounts Receivables(300M)300M000
Inventory0(300M)000
Accounts Payables818K2.37M(7.58M)1.81M6.04M
Other Working Capital410.44M249.26M(108.88M)(112.03M)(137.06M)
Other Non-Cash Items142.1M(38.48M)(18.87M)(2.87M)(250.63M)
Operating Cash Flow(66.27M)22.53M(149.2M)(347.25M)(345.1M)
Capital Expenditures(46.81M)(48.95M)(33.73M)(8.95M)(14.95M)
Acquisitions (Net)620K412.39M00(78K)
Purchases of Investments(777.22M)(1.62B)(984.34M)(486.44M)(1.21B)
Sales of Investments529.27M1.2B1.09B680.39M848.63M
Other Investing Activities0(412.39M)00254.75M
Investing Cash Flow(294.14M)(461.34M)71.84M185.01M(121.44M)
Debt Repayment(2.12M)(2.29M)(2.25M)(485K)0
Common Stock Issued757.45M108.26M270.17M8.22M478.05M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities810K5.62M8.53M00
Financing Cash Flow756.14M111.59M276.45M7.74M478.05M
Effect of Forex Changes00000
Net Change in Cash395.73M(327.22M)199.09M(154.5M)11.51M
Free Cash Flow(113.08M)(26.42M)(182.93M)(356.19M)(360.05M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$80.0M
+ D&A$22.3M
+ Stock-Based Comp$94.2M
+ Deferred Tax$0
- Working Capital-$131.0M
- Other Non-Cash-$250.6M
= Operating Cash Flow-$345.1M
- Capex-$14.9M
= Free Cash Flow-$360.0M

Analysis

FY2025 free cash flow is -$360.0M. FCF conversion is 450.1% of net income. Operating cash flow was -$345.1M, with capex of -$14.9M. The largest bridge item is Other Non-Cash at -$250.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipOct 16, 2026
4Statement of changes in beneficial ownershipOct 2, 2026

Does BEAM generate free cash flow?

Beam Therapeutics Inc. (BEAM) generated -$360.05M of free cash flow in fiscal 2025.

How much operating cash flow does BEAM produce?

Operating cash flow was -$345.10M, before capital expenditures of $14.95M.